Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Population pharmacokinetics of gabapentin in patients with neuropathic pain: lack of effect of diabetes or glycaemic control.

< BACK TO ARCHIVE


2020 Oct 28


Br J Clin Pharmacol


http://www.ncbi.nlm.nih.gov/pubmed/33118231?dopt=Abstract

Population pharmacokinetics of gabapentin in patients with neuropathic pain: lack of effect of diabetes or glycaemic control.

Authors

Population pharmacokinetics of gabapentin in patients with neuropathic pain: lack of effect of diabetes or glycaemic control.
Conchon Costa A C, de Lima Benzi J R, Yamamoto P A, Foss de Freitas M C, Albuquerque de Paula F J, Zanelli C F, Lauretti G R, de Moraes N V
Br J Clin Pharmacol. 2020 Oct 28.
PMID: 33118231.

Abstract

Gabapentin (GBP) is widely used to treat neuropathic pain, including diabetic neuropathic pain. Our objective was to evaluate the role of diabetes and glycaemic control on GBP population pharmacokinetics (PopPK).
Read This Paper